Hovione strengthens its global position as a top employer
The certification is granted to Hovione's four manufacturing sites for the third consecutive year.
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
The certification is granted to Hovione's four manufacturing sites for the third consecutive year.
The Medicine Maker, 13 February 2026
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
News release, 29 April 2025
Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Carcinoma - the third leading cause of cancer-related deaths worldwide
Easy-to-use, single-use capsule-based nasal DPI.
Scientist Live, 12 May 2025